NSE: TORNTPHARM | BSE: 500420

Expensive Star

Download real time

3698.80 -31.80 (-0.85%)

New 52W High in past week

44,018 NSE+BSE Volume

NSE 31 Jul, 2025 9:37 AM (IST)

125,184.2

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Estimates Beat

Torrent Pharmaceuticals' Q1FY26 revenue grows 8.9% YoY, beats Forecaster estimates by 0.5% See details

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

08 Feb 2018

3698.80

-0.85%

Margins expand; Improvement in US business remains key

Neutral: Torrent Pharmaceuticals Ltd.

Motilal Oswal

Margins expand; Improvement in US business remains key TRP reported sales of INR14.3b (+4.5% YoY; ~5% miss) in 3QFY18. The miss on revenue can be attributed to a decline in the US and Brazilian businesses. India business grew 22% YoY to INR6.1b (~23% growth adj. for GST). EBITDA increased 14% YoY to INR3.53b (est. of INR3.62b). Margin expanded ~195bp YoY (+130bp QoQ), primarily due to a favorable product mix toward higher-margin branded products. PAT declined 72% YoY to INR580m, mainly due to a one-time impact of the Unichem acquisition and the re-measurement of deferred tax on account...

ICICI Securities Limited increased Hold price target of Torrent Pharmaceuticals Ltd. to 3530.0 on 29 Jul, 2025.

Torrent Pharmaceuticals Ltd.

07 Nov 2017

3698.80

-0.85%

Result Review of Torrent Pharmaceuticals

Accumulate: Torrent Pharmaceuticals Ltd.

Target

IDBI Capital

Upward estimates for FY19 and rating to ACCUMULATE We expect the Unichem dheal to take a closure by 31/12/2017, hence expecting some pain on the BS for FY18E with increased Debt and reduced Cash, however, with synergies with the deal and traction in the other regions and higher number of launches in the US would provide impetus to the valuation. We expect sales to grow...

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

07 Nov 2017

3698.80

-0.85%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues came in flat YoY at | 1429 crore, below I-direct estimate of | 1542 crore mainly due to 21% YoY decline in the US to | 255 crore (I-direct estimate: | 281 crore) and 24% YoY decline in Brazil to | 120 crore (I-direct estimate: | 188 crore). Domestic business, on the other hand, grew 22% YoY to | 607 crore (I-direct estimate: | 546 crore) EBITDA margins were flat at 23% YoY (I-direct estimate: 21.0%). EBITDA remained flat YoY at | 329 crore...

ICICI Securities Limited increased Hold price target of Torrent Pharmaceuticals Ltd. to 3530.0 on 29 Jul, 2025.

Torrent Pharmaceuticals Ltd.

06 Nov 2017

3698.80

-0.85%

Torrent Pharma (2QFY18): Entering the big leagues. Maintain BUY

Buy: Torrent Pharmaceuticals Ltd.

Target

HDFC Securities

Owing to the enhanced business mix, which will ensure the sustainability of future cash flows, we have increased our assigned earnings multiple from 20x to 22x, and maintain BUY with a TP of Rs 1,480 (22x Sep-19E). After the acquisition of Unichem Labs (UL) domestic portfolio, Torrent Pharma (TRP) will become the fifth largest player in the Rs 1.14tn Indian Pharma market (IMS data). Closed at a value of Rs 36bn, this deal will (1) Further strengthen TRPs position in CVS, CNS and GI categories owing to a complementary sub-therapy presence, (2) Add ~3,000 employees (including MRs) and provide access to an additional 2,100 stockists pan-India, (3) Give TRP an entry into the Indian OTC market, with the growing Unienzyme brand of UL.

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

05 Nov 2017

3698.80

-0.85%

Torrent Pharmaceuticals: Entering big league through this acquisition

Neutral: Torrent Pharmaceuticals Ltd.

Recommendation Target

Motilal Oswal

Big leap- to become top-5 player: Torrent has entered into a definitive agreement with Unichem to acquire its branded business of India and Nepal for INR36b on slump sale basis (transaction closure expected by 2017 end). Through this acquisition, Torrent will acquire >120 brands in India and Nepal and manufacturing plant at Sikkim. Building leadership position through strings of acquisitions: This is the fifth acquisition in India by Torrent pharma in last 4 years (Brands from Elder and Novartis, manufacturing plants from Zyg Pharma and Glochem). According to...

ICICI Securities Limited increased Hold price target of Torrent Pharmaceuticals Ltd. to 3530.0 on 29 Jul, 2025.

Torrent Pharmaceuticals Ltd.

01 Aug 2017

3698.80

-0.85%

Torrent Pharma (1QFY18): Margin beat. Maintain BUY

Buy: Torrent Pharmaceuticals Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 1,450 (20x Jun-19E). Despite a 9% decline in the India business, sequentially flat sales in the US and strong rupee appreciation during the last quarter, Torrent Pharma (TRP) reported 100bps QoQ improvement in EBITDA margin (21.6%) and 500bps higher gross margin, leading to a PAT of Rs 1.8bn (57% beat on our earnings estimates). Management has attributed this to the improved product mix in the US and Brazil markets, and price hikes in the India business.

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

01 Aug 2017

3698.80

-0.85%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Revenues declined 11% YoY to | 1374 crore (I-direct estimate: | 1421 crore) mainly due to high base of gAbilify exclusivity in the US. US revenue declined 37% YoY to | 272 crore (I-direct estimate: | 261 crore). Domestic revenue declined 9% YoY to | 464 crore (Idirect estimate: | 428 crore) mainly due to GST transition EBITDA margins declined to 21.6% (I-direct estimate: 20.0%) against 28.3% in Q1FY17. EBITDA fell 32% YoY to | 297 crore Net profit fell 36% YoY to | 188 crore (I-direct estimate: | 164 crore) mainly on account of lower operational performance...

Torrent Pharmaceutic.. has an average target of 3726.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

01 Aug 2017

3698.80

-0.85%

Result Review of Torrent Pharmaceuticals

Accumulate: Torrent Pharmaceuticals Ltd.

IDBI Capital

Q1FY18 revenues were down 10.9% YoY lower than our forecast by 4.6%. EBITDA margin of 20.1% were lower than our estimates of 20.5%, mainly on the back of increased staff and other expenses. However, PAT of Rs1.88bn, -35.6% YoY, was 8.5% lower than our estimates given higher tax rate. India business traction a little slower owing to GST and slower-than-expected pickup from Novartis brands, 8-10 launches in US and volume growth in Brazil to...

Torrent Pharmaceutic.. has an average target of 3726.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

24 Jun 2017

3698.80

-0.85%

Company Update of Torrent Pharmaceuticals

Accumulate: Torrent Pharmaceuticals Ltd.

Target

IDBI Capital

US contribution continues to reduce owing to the pricing pressure in the base business and lower FTF launches. In FY17, TRP filed 17 ANDAs of which 6 were FTFs. Focus on filings in specialty segments like dermatology, oncology and ophthalmology will help sustain EBIDTA. About 5-6 pending launches and with 10-12 launches every year in FY18/19E we estimate US...